Fir Tree Capital Management’s Myriad Genetics MYGN Stock Holding History

Fir Tree Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-306,772	Closed	-$13.2M	–	69
2015 Q4	$13.2M	Sell	306,772 -375,303	-55%	-$15.9M	0.24%	45
2015 Q3	$25.6M	Sell	682,075 -164,346	-19%	-$5.83M	0.43%	35
2015 Q2	$28.8M	Sell	846,421 -266,493	-24%	-$9.06M	0.46%	31
2015 Q1	$39.4M	Sell	1,112,914 -538,119	-33%	-$19.3M	0.56%	35
2014 Q4	$56.2M	Hold	1,651,033	–	–	0.59%	43
2014 Q3	$63.7M	Hold	1,651,033	–	–	0.71%	39
2014 Q2	$64.3M	Hold	1,651,033	–	–	0.7%	41
2014 Q1	$56.4M	Sell	1,651,033 -546,338	-25%	-$16.9M	0.63%	39
2013 Q4	$46.1M	Buy	+2,197,371	New	+$55.6M	0.52%	42

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

SCM

Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RIM

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Fir Tree Capital Management's MYGN Position: Q1 2016 in Review

Fir Tree Capital Management sold out of Myriad Genetics (MYGN) in Q1 2016, closing a stake of 306,772 shares — an estimated $13.2M sold.

Fir Tree Capital Management first reported a position in MYGN in Q4 2013 and held it in 9 quarters. The position peaked at $64.3M in Q2 2014. 234 funds tracked by Wall St. Rank hold MYGN as of Q1 2016.

Fir Tree Capital Management reported no remaining Myriad Genetics position as of Q1 2016 after selling out during the quarter.
Fir Tree Capital Management sold 306,772 Myriad Genetics shares in Q1 2016, an estimated $13.2M.
Fir Tree Capital Management first reported a position in Myriad Genetics in Q4 2013 and held it in 9 quarters.
Fir Tree Capital Management's Myriad Genetics position peaked at $64.3M in Q2 2014.
234 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2016.

Based on Fir Tree Capital Management's 13F filing for Q1 2016, filed 16 May 2016.